In a report issued on January 4, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Bausch Health Companies Inc (BHC), with a price target of $39. The company’s shares closed on Friday at $21.25.
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 4.8% and a 39.3% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Assertio Therapeutics Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch Health Companies Inc with a $31.50 average price target, a 48.2% upside from current levels. In a report issued on January 1, Piper Jaffray also upgraded the stock to Buy with a $27 price target.
.
See today’s analyst top recommended stocks >>
Based on Bausch Health Companies Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $350 million. In comparison, last year the company earned revenue of $2.16 billion and had a net profit of $513 million.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
Read More on BHC:
